IMRX

TentativeAI Memo

Immuneering

As of 2026-10-14/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

November 6 SITC poster • 2026-11-06

Base target: $3 / p=0% prob

Biggest risk

The main efficacy claim rests on single-arm and exploratory data; Phase 3 enrollment, safety, comparator performance and timing could disappoint. Company-reported Q2 cash and securities of $182.7 million and anticipated runway into 2029 reduce immediate financing pressure but do not remove trial or future dilution risk. [#PR-EARNINGS-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm

Invalidation

Break below $2 or thesis failure.

What would change my mind?

Atebimetinib plus chemotherapy produced 17.3-month median overall survival in 55 first-line pancreatic-cancer patients in a single-arm Phase 2a study. The September exploratory analysis also linked weight stability with longer survival, but it does not prove treatment benefit against a randomized control. Phase 3 confirmation is the decisive upside test. [#PR-EARNINGS-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm; https://immuneering.gcs-web.com/news-releases/news-release-details/immuneering-presents-data-2026-aacr-conference-pancreatic-cancer

Research note

Recommendation

—

Confidence

medium

As of

2026-10-14

Base target

p=0%

Bull target

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MAPKeeper 301 pivotal readout
Atebimetinib plus chemotherapy produced 17.3-month median overall survival in 55 first-line pancreatic-cancer patients in a single-arm Phase 2a study.
The September exploratory analysis also linked weight stability with longer survival, but it does not prove treatment benefit against a randomized control.

BearKey bullets

MAPKeeper 301 site activation, enrollment, safety or randomized efficacy could fall short; the anticipated mid-2028 readout is distant.
Q2 R&D expense rose to $14.0 million from $10.5 million a year earlier; expanding trials may increase cash use despite the company's anticipated runway into 2029.
[#PR-EARNINGS-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm

WatchKey bullets

November 6 SITC poster

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $3 (p=0%)

Target spread vs base: +103% / -50%

Scenario probabilities

Bull Target: $7 (p=0%)Base Target: $3 (p=0%)Bear Target: $2 (p=0%)

Commentary

Company disclosures provide substantive trial context, but the packet has no recent trusted-news, price-reaction, social, options or analyst-revision series. The sentiment numeric fields are unavailable, not measured zeros. The structured prior is negative across 5–120 days despite strong primary-source evidence; near-term posters and dosing milestones are lower-signal than the distant randomized readout.

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

MAPKeeper 301 pivotal readout

Scenarios

Bull Target (Scenario probability)

$7 / p=0% prob

Base Target (Scenario probability)

$3 / p=0% prob

Bear Target (Scenario probability)

$2 / p=0% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-06
November 6 SITC poster
Immuneering plans to present preclinical atebimetinib plus PD-1 blockade findings on November 6. The poster may inform interest in the planned lung-cancer study, but preclinical results do not establish patient benefit. [#IR-2026-10-02] https://immuneering.gcs-web.com/news-releases/news-release-details/immuneering-present-41st-annual-meeting-society-immunotherapy
Prob 90.00% • Move 3.00% • Priced-in 65.00%
EVENT2026-12-31
Planned lung-cancer Phase 2 first dosing
The August company release targeted first dosing of atebimetinib plus anti-PD-1 in non-small-cell lung cancer during the second half of 2026, with preliminary data expected in late 2027. Confirming or missing the dosing target would test execution, not efficacy. [#PR-EARNINGS-2026-08-05] [#8-K-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm
Prob 65.00% • Move 5.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

MAPKeeper 301 pivotal readout
2028-06-30
The randomized Phase 3 pancreatic-cancer trial is underway; the August company release anticipated topline data in mid-2028. Earlier single-arm Phase 2a survival and tolerability findings remain unconfirmed by a randomized comparison. [#PR-EARNINGS-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm
Prob 55% • Move 60% • Priced-in 35%

Risks

MAPKeeper 301 site activation, enrollment, safety or randomized efficacy could fall short; the anticipated mid-2028 readout is distant.
Q2 R&D expense rose to $14.0 million from $10.5 million a year earlier; expanding trials may increase cash use despite the company's anticipated runway into 2029. [#PR-EARNINGS-2026-08-05] https://www.sec.gov/Archives/edgar/data/1790340/000179034026000088/imrx-20260805xexx991.htm
Single-arm Phase 2a survival cannot establish an advantage over standard care; the September weight analysis was exploratory and post hoc.
The near-term SITC presentation concerns preclinical models, not clinical lung-cancer outcomes.

Peers

Symbol	Summary
GLSI	Small-cap oncology development-stage comparison from the packet; not established as a same-indication or same-trial-stage peer.
ZNTL	Broad clinical-oncology comparison from the packet. Differences in assets and trial risk limit valuation read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

GLSI

Small-cap oncology development-stage comparison from the packet; not established as a same-indication or same-trial-stage peer.

ZNTL

Broad clinical-oncology comparison from the packet. Differences in assets and trial risk limit valuation read-through.